Research programme: antibody drug conjugates - MacroGenics

Drug Profile

Research programme: antibody drug conjugates - MacroGenics

Alternative Names: MGC-018

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MacroGenics
  • Developer MacroGenics; Synthon
  • Class Bispecific antibodies; Drug conjugates; Recombinant proteins
  • Mechanism of Action CD276 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics and Pharmacokinetics data from in vitro and preclinical studies presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 21 Dec 2016 MacroGenics announces intention to submit an IND in 2018 (MacroGenics Form 8-K, filed in December 2016).
  • 12 Dec 2016 MacroGenics in-licenses linker-drug technology from Synthon Biopharmaceuticals for MGC 018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top